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Clostridium difficile1,2
Spore forming, anaerobic gram positive bacillus
Spread via fecal-oral route
Produces and releases toxins A and B
Symptoms ranging from asymptomatic carrier, to diarrhea, to colitis,
or to pseudomembranous colitis.
Clostridium difficile infection (CDI)
Rising concern in hospitals and long term care facilities due to
patients being prescribed antimicrobial(s) and exposure to organisms

Exposure to broad-spectrum antibiotics1,2
Exposure to the organism1,2
Other risk factors: reduced gastric acid, immunosuppressive therapy,
serious underlying illness and co-morbidities, gastrointestinal surgery,
long duration of hospitalization, advanced age, etc. 1,2

Three month pilot study from September 2015 to December 2015
An electronic medical record system, Vigilanz™, provided daily reports
scoring patients based on risk factors shown under Data Collection Sheet
Patients with a score of three or higher were defined high risk
High risk patients were reviewed by the pharmacist and appropriate CDI
preventative recommendations were noted in the patient’s chart or via
recommendations to attending physicians during multidisciplinary rounds

Percentage of high risk patients on the floor
Cases of hospital onset CDI
Percentage of pharmacist interventions accepted
Type and method of intervention accepted
Percentage of inappropriate PPI use

Antibiotic Stewardship1,2
Hand hygiene and barrier precautions1,2
Discontinue proton pump inhibitors (PPIs) to prevent CDI recurrence.3
American Society of Health System Pharmacists (ASHP) Guidelines 4
Recommends stress ulcer prophylaxis (SUP) with gastric acid
suppressants for patients in the intensive care unit (ICU) meeting
specific criteria
SUP for adult patients in non-ICU settings are not recommended
Probiotics may have moderate effectiveness in primary prevention of
CDI.5
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The purpose of this study is to appropriately evaluate patients at risk of
developing CDI, and to appropriately discontinue offending agents, if
warranted, for patients identified as being high risk for developing CDI.
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